Rules of Origin for medicaments (formulations) — Dubai (UAE) to India
HS 30049099 · Pharmaceuticals · Rules of Origin & preferential rate
Data last updated: · MFN duty & IGST verified against ICEGATE (Indian Customs EDI). Rules of Origin per CEPA Annex 3B. Verify your exact HS line before filing.
- CEPA eligible
- Yes
- Value addition (RVC)
- 40%
- Tariff-classification change
- CTSH Annex 3B rule set at chapter level — it covers the whole chapter, not this code alone
- MFN → CEPA basic duty
- 10% → 0%
Rule of Origin (CEPA Annex 3B, primary source): Chapter 30: CTSH + VA 40%
Qualifying under the Rules of Origin
To claim the CEPA preference on medicaments (formulations) (HS 30049099), the goods must qualify as UAE-originating. The Product-Specific Rule (Annex 3B) is "Chapter 30: CTSH + VA 40%": the goods must undergo a change of tariff sub-heading (CTSH) AND add at least 40% regional value content — both conditions, not either/or. Read that rule for what it is: Annex 3B supplies it at chapter level, so it governs hundreds of eight-digit codes rather than this one. It is the correct rule to apply, and it is also the place to check for a more specific carve-out before committing to a claim. Finished formulations enter at a 10% MFN basic duty which CEPA removes entirely, with 18% IGST recoverable as input credit. Origin is the binding test, not the tariff: the rule is a change of sub-heading plus 40% value addition, and UAE pharma operations typically formulate, fill and pack using active ingredients imported from India or China. The shift from bulk API to dosage form usually clears the classification limb; the value-addition limb often does not. Clearance is slower than the duty suggests — CDSCO import registration and a licence under the Drugs and Cosmetics Act must be in hand before arrival, and scheduled formulations remain under price control. One addition on the rate itself: medicaments reach zero immediately rather than through a phase-down, so there is no schedule step to track here — unlike much of the corpus, the number on this page does not change year to year. What does change is the registration position, since CDSCO licences are product- and site-specific and a change of contract manufacturer restarts them. A valid Certificate of Origin filed through the eCoO 2.0 system must accompany the shipment; without it, customs charges the 10% MFN rate instead of the preference.
Check your own figures in the Rules of Origin (RVC) qualifier. Qualifying is only half of it — the preference is claimed with a Certificate of Origin, issued in the UAE before shipment or retrospectively within 12 months.
Frequently asked questions
- Does medicaments (formulations) qualify for India–UAE CEPA?
- Yes, if it meets the Annex 3B Product-Specific Rule "Chapter 30: CTSH + VA 40%": it must BOTH change tariff classification (CTSH) AND add at least 40% regional value content — both conditions are required, not either/or.
- What is the Rule of Origin for medicaments (formulations)?
- Per CEPA Annex 3B: Chapter 30: CTSH + VA 40%. RVC% = [(FOB − value of non-originating materials) / FOB] × 100 (FOB basis).
- What proof is needed at import?
- A preferential Certificate of Origin filed through eCoO 2.0, presented at customs before clearance. Without it, the 10% MFN duty applies.